Rate this post

Ganjapreneur report,

According to Griffiths, it will be “completely new and more of the same,” meaning he and his research team will continue to lead investigations into the potential benefits of psychedelics like psilocybin in the treatment of many conditions such as addiction, including alcoholism and nicotine dependence; post-traumatic stress disorder; anorexia; Alzheimer’s; Lyme disease; and more. What’s new, however, is that the FDA is beginning to warm up to the idea of psychedelics having medicinal potential, despite being categorized as Schedule 1 substances with supposedly zero medicinal value.

Read full article:  https://www.ganjapreneur.com/worlds-largest-psilocybin-research-center-launches-at-johns-hopkins/

Here’s the site https://hopkinspsychedelic.org/

They write, “At the Center for Psychedelic and Consciousness Research, researchers will focus on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health. Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa and alcohol use in people with major depression. The researchers hope to create precision medicine treatments tailored to the specific needs of individual patients. ”